혈액암 (AML/ALL)

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

CGTBiologicstaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4

CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3

CGTBiologicstaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#세포유전치료#CAR-T+2

CGTBiologicstaleAdaptimmunePreclinical

Genetically engineered T Cell Receptors (Genetically engineered T Cell Receptors)

Solid and Hematological Malignancies · Solid and Hematological Malignancies

#SolidandHematologicalMalignancie#CGT#Preclinical#세포유전치료#CAR-T+2

AntibodystaleRochePhase 1

HDMP + rituximab as a means of debulking prior to initiating venetoclax. (HDMP + rituximab as a means of debulking prior to initiating venetoclax.)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia or Small Ly

#ChronicLymphocyticLeukemiaorSmal#Antibody#Phase1#항체#면역항체+2

효능 ORR 1%임상시험 1상태 RECRUITING

CGTBiologicstaleEver Supreme Bio Technology Co.…Phase 2

HLA-G-CAR.BiTE allogeneic γδ T cells (HLA-G-CAR.BiTE allogeneic γδ T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

AntibodystaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3